Los factores de riesgo tradicionales no explicarían el exceso de mortalidad en los diabéticos mayores de 60 años.
Traditional Risk Factors Alone Coluld Not Explain the Excess Mortality in Patients with Diabets: A National cohort study of Spanish older adults.
Comentario: Dr. Mateu Seguí Díaz
http://care.diabetesjournals.org/content/early/2012/08/05/dc11-1615.full.pdf
Traditional Risk Factors Alone Coluld Not Explain the Excess Mortality in Patients with Diabets: A National cohort study of Spanish older adults.
Comentario: Dr. Mateu Seguí Díaz
http://care.diabetesjournals.org/content/early/2012/08/05/dc11-1615.full.pdf
La insulina glargina no comportó beneficios cardiovasculares ni aumentó el riesgo de cáncer en el Estudio ORIGIN.
Basal insulin and other outcomes in dysglycemia.
Comentario: Dr. Manel Mata Cases
http://www.nejm.org/doi/full/10.1056/NEJMoa1203858
Basal insulin and other outcomes in dysglycemia.
Comentario: Dr. Manel Mata Cases
http://www.nejm.org/doi/full/10.1056/NEJMoa1203858
En pacientes diabéticos tipo 2 sin retinopatía previa. ¿Es seguro un cribado cada 2 años?
Increased to 2 Years for Type 2 Diabetic Patients without Retinopathy?
Comentario: Dr. Joan Barrot de la Puente
http://care.diabetesjournals.org/content/35/8/1663.full.pdf
Increased to 2 Years for Type 2 Diabetic Patients without Retinopathy?
Comentario: Dr. Joan Barrot de la Puente
http://care.diabetesjournals.org/content/35/8/1663.full.pdf
Incremento de la mortalidad en los pacientes que presentan hipoglucemias severas.
Increased mortality of patients with Diabetes reporting Severe Hypoglycemia
Comentario: Dr Fernando Álvarez Guisasola
http://care.diabetesjournals.org/content/early/2012/06/11/dc11-2054.full.pdf
Increased mortality of patients with Diabetes reporting Severe Hypoglycemia
Comentario: Dr Fernando Álvarez Guisasola
http://care.diabetesjournals.org/content/early/2012/06/11/dc11-2054.full.pdf
Remisión de la diabetes en el estudio Look Ahead.
Association of an intensive lifestyle intervention with remission of type 2 diabetes.
Comentario: Dr. Mateu Seguí Diaz
http://jama.jamanetwork.com/article.aspx?articleid=1486829
Association of an intensive lifestyle intervention with remission of type 2 diabetes.
Comentario: Dr. Mateu Seguí Diaz
http://jama.jamanetwork.com/article.aspx?articleid=1486829
Conferencia de consenso: Tratamiento de la diabetes tipo 2 en el paciente anciano
Comentario: Dr. Javier Díez Espino.
http://zl.elsevier.es/es/revista/medicina-clinica-2/articulo/tratamiento-diabetes-tipo-2-el-90186440
Comentario: Dr. Javier Díez Espino.
http://zl.elsevier.es/es/revista/medicina-clinica-2/articulo/tratamiento-diabetes-tipo-2-el-90186440
Metformina vs glipizida: Eventos cardiovasculares en un ensayo clínico en pacientes con diabetes tipo 2 y enfermedad coronaria
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Comentario: Dr. José Luis Torres Baile
http://care.diabetesjournals.org/content/early/2012/12/07/dc12-0719.full.pdf
Effects of Metformin Versus Glipizide on Cardiovascular Outcomes in Patients With Type 2 Diabetes and Coronary Artery Disease
Comentario: Dr. José Luis Torres Baile
http://care.diabetesjournals.org/content/early/2012/12/07/dc12-0719.full.pdf
Efectos de la cirugía bariátrica sobre la diabetes y otros factores de riesgo cardiovascular.
Bariatric surgery and cardiovascular outcomes: a systematic review. Comentario: Dr José Juan Alemán Sánchez
Heart. 2012 Dec;98(24):1763-77. doi: 10.1136/heartjnl-2012-301778
Bariatric surgery and cardiovascular outcomes: a systematic review. Comentario: Dr José Juan Alemán Sánchez
Heart. 2012 Dec;98(24):1763-77. doi: 10.1136/heartjnl-2012-301778
Dudas sobre la seguridad cardiovascular de las sulfonilureas.
Cardiovascular safety of sulfonylureas: a metanalysis of randomized clinical trials
Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116 (Epub ahead of print)
Comentario: Dr. Mateu Seguí Diaz
Cardiovascular safety of sulfonylureas: a metanalysis of randomized clinical trials
Diabetes Obes Metab. 2013 Apr 17. doi: 10.1111/dom.12116 (Epub ahead of print)
Comentario: Dr. Mateu Seguí Diaz
Prevalencia de la enfermedad renal en pacientes diabéticos tipo 2 en España: Estudio PERCEDIME2.
Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
BMC Nephrology. 2013; 14:46 doi: 10.1186/1471-2369-14-46
Comentario: Dr. Xavier Mundet Tudurí
Prevalence of chronic kidney disease in patients with type 2 diabetes in Spain: PERCEDIME2 study
BMC Nephrology. 2013; 14:46 doi: 10.1186/1471-2369-14-46
Comentario: Dr. Xavier Mundet Tudurí
Seguridad cardiovascular de los IDPP4.
Diperptidyl peptidase 4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2013; 15:112-120
Comentario: Dr. José Javier Mediavilla Bravo
Diperptidyl peptidase 4 inhibitors and cardiovascular risk: A meta-analysis of randomized clinical trials.
Diabetes Obes Metab. 2013; 15:112-120
Comentario: Dr. José Javier Mediavilla Bravo
Análogos del GLP-1 vs insulina: Efectividad en Atención Primaria.
Primary-care receptor agonist and insulin in the UK
Diabet Med. 2013 Jun; 30(6):681-6
Comentario: Dr. Francisco Javier García Soidán
Primary-care receptor agonist and insulin in the UK
Diabet Med. 2013 Jun; 30(6):681-6
Comentario: Dr. Francisco Javier García Soidán
